280 related articles for article (PubMed ID: 37886900)
1. Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women-What Is the Evidence?
Hirschberg AL
J Clin Endocrinol Metab; 2024 Apr; 109(5):1202-1213. PubMed ID: 37886900
[TBL] [Abstract][Full Text] [Related]
2. PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis.
Millán-de-Meer M; Luque-Ramírez M; Nattero-Chávez L; Escobar-Morreale HF
Hum Reprod Update; 2023 Nov; 29(6):741-772. PubMed ID: 37353908
[TBL] [Abstract][Full Text] [Related]
3. Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman.
Hirschberg AL
J Clin Endocrinol Metab; 2023 Apr; 108(5):1243-1253. PubMed ID: 36409990
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome.
Lambrinoudaki I
Maturitas; 2011 Jan; 68(1):13-6. PubMed ID: 20943333
[TBL] [Abstract][Full Text] [Related]
5. No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours.
Pelusi C; Forlani G; Zanotti L; Gambineri A; Pasquali R
Clin Endocrinol (Oxf); 2013 Apr; 78(4):533-8. PubMed ID: 22583337
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk factors and events in women with androgen excess.
Macut D; Antić IB; Bjekić-Macut J
J Endocrinol Invest; 2015 Mar; 38(3):295-301. PubMed ID: 25432327
[TBL] [Abstract][Full Text] [Related]
7. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
8. The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome.
Barber TM; Vojtechova P; Franks S
Horm Mol Biol Clin Investig; 2013 Sep; 15(3):91-103. PubMed ID: 25436736
[TBL] [Abstract][Full Text] [Related]
9. Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome.
Zhao X; Zhong J; Mo Y; Chen X; Chen Y; Yang D
Int J Gynaecol Obstet; 2010 Feb; 108(2):148-51. PubMed ID: 19932893
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hyperandrogenism.
Yoldemir T
Climacteric; 2022 Apr; 25(2):109-117. PubMed ID: 33988479
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic biomarkers in women with polycystic ovary syndrome.
van der Ham K; Louwers YV; Laven JSE
Fertil Steril; 2022 May; 117(5):887-896. PubMed ID: 35512973
[TBL] [Abstract][Full Text] [Related]
12. Androgens in Menopausal Women: Not Only Polycystic Ovary Syndrome.
Kostakis EK; Gkioni LN; Macut D; Mastorakos G
Front Horm Res; 2019; 53():135-161. PubMed ID: 31499509
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of PCOS and related hyperandrogenic traits in premenopausal women with type 1 diabetes: a systematic review and meta-analysis.
Bayona A; Martínez-Vaello V; Zamora J; Nattero-Chávez L; Luque-Ramírez M; Escobar-Morreale HF
Hum Reprod Update; 2022 Jun; 28(4):501-517. PubMed ID: 35237802
[TBL] [Abstract][Full Text] [Related]
14. Telomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome.
Velazquez ME; Millan AL; Rojo M; Abruzzese GA; Cocucci SE; Iglesias Molli AE; Frechtel GD; Motta AB; Cerrone GE
Front Endocrinol (Lausanne); 2021; 12():604215. PubMed ID: 34054718
[TBL] [Abstract][Full Text] [Related]
15. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis.
Wekker V; van Dammen L; Koning A; Heida KY; Painter RC; Limpens J; Laven JSE; Roeters van Lennep JE; Roseboom TJ; Hoek A
Hum Reprod Update; 2020 Nov; 26(6):942-960. PubMed ID: 32995872
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.
Jones H; Sprung VS; Pugh CJ; Daousi C; Irwin A; Aziz N; Adams VL; Thomas EL; Bell JD; Kemp GJ; Cuthbertson DJ
J Clin Endocrinol Metab; 2012 Oct; 97(10):3709-16. PubMed ID: 22837189
[TBL] [Abstract][Full Text] [Related]
17. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
18. Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition.
Polotsky AJ; Allshouse AA; Crawford SL; Harlow SD; Khalil N; Kazlauskaite R; Santoro N; Legro RS
J Clin Endocrinol Metab; 2014 Jun; 99(6):2120-7. PubMed ID: 24517154
[TBL] [Abstract][Full Text] [Related]
19. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study.
Pinola P; Lashen H; Bloigu A; Puukka K; Ulmanen M; Ruokonen A; Martikainen H; Pouta A; Franks S; Hartikainen AL; Järvelin MR; Morin-Papunen L
Hum Reprod; 2012 Nov; 27(11):3279-86. PubMed ID: 22933528
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive evaluation of disparities in cardiometabolic and reproductive risk between Hispanic and White women with polycystic ovary syndrome in the United States: a systematic review and meta-analysis.
Kazemi M; Kim JY; Wan C; Xiong JD; Parry SA; Azziz R; Lujan ME
Am J Obstet Gynecol; 2022 Feb; 226(2):187-204.e15. PubMed ID: 34384776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
